Cover Image

Patterns of Constitutive and Inducible Clindamycin Resistance in Staphylococcus aureus Isolated from Clinical Samples by D-test Method, Shiraz, Southwest of Iran

Mohammad Motamedifar, Hadi Seddigh Ebrahim Sarai, Davood Mansury

Background: Macrolides, Lincosamides and type B Streptogramins (MLSB) are commonly used for the treatment of Staphylococcal infections. Inducible MLSB resistance (iMLSB) cannot be identified by standard methods of antibiotic susceptibility testing. D-test appears to be a reliable indicator of iMLSB strains. The aim of this study was to determine the prevalence of Clindamycin resistance phenotypes in Staphylococcus aureus (S.aureus) isolated from clinical samples in Shiraz, southwest of Iran.Materials and Methods: This cross-sectional study was performed on a total of 302 S. aureus isolates which were collected from two teaching hospitals in Shiraz during 2012. Methicillin resistant Staphylococcus aureus (MRSA) were screened based on their resistance to 30μg Cefoxitin disk. 168 Methicillin-sensitive Staphylococcus aureus (MSSA) and 134 MRSA isolates were tested in this study. The isolates were tested for susceptibility to Clindamycin (2 µg) and Erythromycin (15 µg) by Clinical and Laboratory Standards Institute (CLSI) recommended disk diffusion test.Results: Of 302 collected S. aureus isolates, 134 (44.4%) were MRSA and 168 (55.6%) were MSSA. Inducible MLSB resistance was observed in 10.4% of all recovered MRSA and 3% of all MSSA isolates. The majority of MRSA isolates (77.6%) constituted MLSB phenotype (cMLSB); this phenotype was seen in 4.1% of our tested MSSA isolates. Finally, 12.0% of MRSA isolates and 89.9% of MSSA showed sensitivity to both Erythromycin and Clindamycin.Conclusion: Different resistance patterns in hospitals indicated that performing routine D-test for S. aureus infections is highly recommended for each medical center. [GMJ. 2014;3(4):216-21]


D-test, Inducible clindamycin resistance, Staphylococcus aureus

.DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009;119(9):2464-74.

Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;1(46):533590.

Nakajima Y. Mechanisms of bacterial resistance to macrolide antibiotics. J Infect Chemother. 1999;5(2):61-74.

Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci.J ClinMicrobiol. 2003;41(10):4740-4.

Hamilton-Miller JM, Shah S. Patterns of phenotypic resistance to the macrolide-lincosamide-ketolide-streptogramin group of antibiotics in staphylococci. J AntimicrobChemother. 2000;46(6):941-9.

Yilmaz G, Aydin K, Iskender S, Caylan R, Koksal I. Detection and prevalence of inducible clindamycin resistance in staphylococci. J Med Microbiol. 2007;56(3):342-5.

Steward CD, Raney PM, Morrell AK, Williams PP, McDougal LK, Jevitt L, et al. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J ClinMicrobiol. 2005;43(4):1716-21.

Masterton R. The importance and future of antimicrobial surveillance studies. Clin Infect Dis. 2008;15(47):590063.

Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc. 1999; 74(8):825-33.

Drinkovic D, Fuller ER, Shore KP, Holland DJ, Ellis-Pegler R. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance: J AntimicrobChemother. 2001; 48(2):315-6.

Frank AL, Marcinak JF, Mangat PD, Tjhio JT, Kelkar S, Schreckenberger PC, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2002;21(6):530-4.

Schreckenberger PC, Ilendo E, Ristow K. Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci in a community and a tertiary care hospital. J Clin Microbiol. 2004;42(6):2777-9.

Seifi N, Kahani N, Askari E, Mahdipour S, Naderi NM. Inducible clindamycin resistance in Staphylococcus aureus isolates recovered from Mashhad, Iran. Iran J Microbiol. 2012;4(2):82-6.

Saderi H, Emadi B, Owlia P. Phenotypic and genotypic study of macrolide, lincosamide and streptogramin B (MLSB) resistance in clinical isolates of Staphylococcus aureus in Tehran, Iran. Med SciMonit. 2011;17(2):48-53.

T. Gunduz SA, G. Ozcolpan and M. E. Limoncu. Investigation of inducible clindamycin resistance among clinical isolates of staphylococci. Afr J Microbiol Res. 2012;6(10):2294-8.

G. Velvizhi GS, N. Palaniappan. Prevalence and Phenotypic Detection of Erythromycin-Induced Resistance to Clindamycin in MRSA Isolates J Clin Diagn Res. 2011;5(6):1195-8.

T. Otsuka, H. Zaraket, T. Takano, K. Saito, S. Dohmae, W. Higuchi, and T. Yamamoto, "Macrolide-lincosamide-streptogramin B resistance phenotypes and genotypes among Staphylococcus aureus clinical isolates in Japan," Clin Microbiol Infect. 2007;13 (3): 325-7.

K. PrabhuSR, and V. Rao. Inducible Clindamycin Resistance in Staphylococcus aureus Isolated from Clinical Samples. J Lab Physicians. 2011;3(1):25-7.

A. Zorgani OS, K. Tawil, E. El-Turki and K.S. Ghenghesh. Inducible Clindamycin Resistance among Staphylococci Isolated from Burn Patients. Libyan J Med. 2009;4(3):104-6.

M. Memariani MP, MH. Shirazi , MM. SoltanDallal , Z. Abdossamadi , N. Mardani. The importance of inducible clindamycin resistance in enterotoxin positive S. aureus isolated from clinical samples. TUMJ. 2009;67(4):250-6

Manjunath MR, Rayapu V , Pragash DS , AnandShaker I and Kasukurthy S. Detection of inducible clindamycin resistance among clinical isolates of staphylococci from a rural tertiary care hospital. Int J Med Res Health Sci. 2013;2(2):182-188

Refbacks

  • There are currently no refbacks.